Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects 18-65 years of old, inclusive~* Documented chronic HCV infection to be of at least 6 months duration and plasma HCV RNA ≥ 5 log10 IU/mL at screening.~* HCV treatment naïve or PEG-IFN, IFN, and/or RBV experienced (treatment must have ceased at least 3 months prior to screening). Treatment experienced subjects should not exceed 40% of the subjects enrolled in each cohort~* Mono-infection with HCV genotype 1a for Cohorts 1, 2, 3, 4, and 5 and mono-infection with HCV genotype 1b for Cohort 6 and 7.~* Estimated creatinine clearance ≥ 70 mL/min,~* QTcF interval ≤ 450 msec for males and ≤ 470 msec for females, QRS duration \< 120 msec, PR interval \< 220 msec,~* Body mass index (BMI) of 19.0 to 34.0 kg/m\^2, inclusive.~Exclusion Criteria:~* Urine drug screen positive for illicit/illegal drugs~* ALT and AST levels \> 5 times the upper limit of the normal range (ULN)~* Direct bilirubin \> ULN, clinical or other laboratory evidence of hepatic decompensation (i.e., platelets \< 90,000/mm\^3, prothrombin time ≥ 1.5 × ULN and albumin \< 3.5 g/dL) are not eligible for study participation.~* Subjects with an absolute neutrophil count (ANC) \< 1,000 cells/mm\^3 (\< 750 cells/mm\^3 for black or African-American subjects), hemoglobin (Hb) \< 11 g/dL,~* Coinfected with hepatitis B virus (HBV), human immunodeficiency virus (HIV), or another HCV genotype other than genotype 1a/b are not eligible for study participation.~* Evidence of hepatocellular carcinoma (e.g., a-fetoprotein \> 50 ng/mL or as indicated by recent ultrasound or other standard of care measure)~* History of significant cardiac disease. The following ECG abnormalities at screening are exclusionary: QTcF (QT corrected using Fridericia's formula=QT/RR\^0.333) \> 450 msec for males and \> 470 for females; QRS \> 120 msec (left or right hemiblock is not exclusionary); PR interval \> 220 msec; bradycardia (\< 45 beats per minute); second or third degree heart block.~* History of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol~* History of a primary gastrointestinal disorder that could interfere with the absorption of the study drug or that could interfere with normal gastrointestinal anatomy or motility

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Multiple-dose, dose-escalation study of GS-9669 (Type: EXPERIMENTAL): Multiple-dose, dose-escalation study of GS-9669, a nonnucleotide NS5B inhibitor of hepatitis C virus (HCV), in subjects with chronic HCV infection. Dosing is planned in up to 7 unique dosing cohorts. Each cohort will be comprised of 10 genotype 1a (Cohorts 1, 2, 3, 4, and 5) or genotype 1b (Cohort 6 and 7), with eight subjects randomized to receive active drug and two subjects randomized to receive placebo per cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).